Intellia raises $150M in follow-on

On Nov. 1, CRISPR company Intellia Therapeutics Inc. (NASDAQ:NTLA) raised $150 million through the sale of 6.3 million shares at $24 in a follow-on underwritten by Credit Suisse, Jefferies and Leerink. The price is a 23% discount to Intellia’s close of $31.12 on Nov. 1, the day before the offering was announced...